| Title |
A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
|
|---|---|
| Published in |
SpringerPlus, October 2015
|
| DOI | 10.1186/s40064-015-1392-x |
| Pubmed ID | |
| Authors |
Maureen Elizabeth Trudeau, Judith-Anne W. Chapman, Baoqing Guo, Mark J. Clemons, Rebecca A. Dent, Roberta A. Jong, Harriette J. Kahn, Kathleen I. Pritchard, Lei Han, Patti O’Brien, Lois E. Shepherd, Amadeo M. Parissenti |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 40% |
| Researcher | 1 | 20% |
| Unknown | 2 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 2 | 40% |
| Medicine and Dentistry | 1 | 20% |
| Unknown | 2 | 40% |